Cancer Research and Treatment

Original Articles

Hematologic malignancy

Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea: Ji Yun Lee, Ji Hyun Kwon, Joon Young Hur, Jun Ho Yi, Ji Hyun Lee, Hyungwoo Cho, Young Rok Do, Jae-Cheol Jo, Hye Jin Kang, Yougil Koh, Won Sik Lee, Sung Nam Lim, Sang Eun Yoon, Seok Jin Kim, Jeong-Ok Lee; Cancer Res Treat. 2024;56(2):681-687. Published online November 10, 2023; DOI: https://doi.org/10.4143/crt.2023.1042

Purpose
Programmed death-1 blockade with pembrolizumab has shown promising activity in relapsed/refractory (R/R) extranodal natural killer/T-cell lymphoma (NKTCL), but studies are limited, with small patient numbers.
Materials and Methods
Thirteen institutes involved with the Consortium for Improving Survival of Lymphoma, a Korean lymphoma study group, collected the clinical data of 59 patients treated with pembrolizumab as salvage therapy between 2016 and 2022.
Results
The median age of the patients was 60 years (range, 22 to 87 years), and 76.3% had advanced Ann Abor stage disease. Pembrolizumab was given to 35.6%, 40.7%, and 23.7% of the patients as second-, third-, and fourth- or higher-line chemotherapy, respectively. The overall response rate was 40.7%, with 28.8% having complete response. The estimated 2-year progression-free survival (PFS) and overall survival rates for all patients were 21.5% and 28.7%, respectively; for responders, the rates were 53.0% and 60.7%, respectively. Although not statistically significant, Eastern Cooperative Oncology Group performance status ≥ 2 (hazard ratio [HR], 1.91; 95% confidence interval [95% CI], 0.93 to 3.94; p=0.078) and stage III or IV disease (HR, 2.59; 95% CI, 0.96 to 6.96; p=0.060) were associated with a trend toward shorter PFS in multivariate analysis. Grade 3 or 4 adverse events (AEs) were noted in 12 patients (20.3%); neutropenia (10.2%), fatigue (6.8%), and pneumonitis (5.1%) were most common AEs.
Conclusion
In conclusion, while pembrolizumab had a modest effect on patients with R/R NKTCL, it may be a useful salvage therapy for patients with localized disease and good performance status.

Citations

Citations to this article as recorded by

Anti-PD-1 antibody combined with P-GEMOX chemotherapy versus P-GEMOX chemotherapy with or without autologous stem-cell transplantation for previously untreated advanced natural killer/T cell lymphoma: a retrospective cohort study
Qihua Zou, Yi Cao, Liang Wang, Wuping Li, Qingsong Yin, Yudan Wu, Hongmei Jing, Zhigang Peng, Xiuhua Sun, Jun Rao, Ying Chen, Hongyu Zhang, Dongfeng Zeng, Bingzong Li, Ying Zhao, Xudong Zhang, Yuchen Zhang, Yan Gao, Bing Bai, Yi Xia, Yu Fang, Zouxiang Che
Blood Cancer Journal.2026;[Epub] CrossRef
Molecular biologic and Epstein-Barr virologic advances in extranodal natural killer/T cell lymphoma over the past four decades
Yasuaki Harabuchi
Auris Nasus Larynx.2026; 53(3): 393. CrossRef
Immunotherapy in NK/T-Cell Lymphoma: Mechanisms, Clinical Evidence, Resistance, and Emerging Multimodal Strategies
Qihao Zhang, Xin Wang
Cancers.2026; 18(9): 1358. CrossRef
Outcomes With First‐Line PD1 Inhibitors in Extranodal NK/T‐Cell Lymphoma: A Comparative Analysis From a 755‐Patient Multicenter Cohort
Hailing Liu, Mei Sun, Chunling Wang, Xiaoqiong Tang, Lixia Sheng, Jie Ma, Xuzhang Lu, Hongming Huang, Jinning Shi, Ran Li, Jing Zhang, Manling Chen, Lei Cao, Haorui Shen, Jianyong Li, Wei Wang, Xia Zhao, Kaiyang Ding, Lei Fan
American Journal of Hematology.2026;[Epub] CrossRef
An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphoma
Yingfang Feng, Xia Liu, Jingwei Yu, Zheng Song, Lanfang Li, Lihua Qiu, Shiyong Zhou, Zhengzi Qian, Xianhuo Wang, Huilai Zhang
Expert Opinion on Biological Therapy.2025; 25(1): 9. CrossRef
Early growth response 1 as a key regulator of PD-L1 expression and immune evasion in extranodal NK/T-cell lymphoma
Ji Yun Lee, Kui-Jin Kim, Woochan Park, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Tae Min Kim, Jin Ho Paik
Blood Cancer Journal.2025;[Epub] CrossRef
Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma
Seok Jin Kim, Jing Quan Lim, Sang Eun Yoon, Deok-Hwan Yang, Ji Hyun Lee, Sung Yong Oh, Yoon Seok Choi, Seong Hyun Jeong, Min Kyoung Kim, Sung Nam Lim, Junhun Cho, Bon Park, Kyung Ju Ryu, Seunghyun Choi, Yoon Park, Kerry May Huifen Lim, Nur Ayuni Binte Muh
Blood.2025; 146(2): 155. CrossRef
Pembrolizumab

Reactions Weekly.2024; 2025(1): 390. CrossRef

6,651 View
258 Download
7 Web of Science
8 Crossref

Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404): Hyungwoo Cho, Dok Hyun Yoon, Dong-Yeop Shin, Youngil Koh, Sung-Soo Yoon, Seok Jin Kim, Young Rok Do, Gyeong-Won Lee, Jae-Yong Kwak, Yong Park, Min Kyoung Kim, Hye Jin Kang, Jun Ho Yi, Kwai Han Yoo, Won Sik Lee, Byeong Bae Park, Jae Cheol Jo, Hyeon-Seok Eom, Hyo Jung Kim, Seong Hyun Jeong, Young-Woong Won, Byeong Seok Sohn, Ji-Hyun Kwon, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2023;55(2):684-692. Published online January 2, 2023; DOI: https://doi.org/10.4143/crt.2022.1434

Abstract PDF Supplementary Material PubReader ePub

Purpose
We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients.
Materials and Methods
Patients with PTCL receiving chemotherapy with curative intent were registered and prospectively monitored. All patients were pathologically diagnosed with PTCL.
Results
A total of 191 patients with PTCL were enrolled in this prospective registry study. PTCL, not otherwise specified (PTCL-NOS) was the most common pathologic subtype (n=80, 41.9%), followed by angioimmunoblastic T-cell lymphoma (AITL) (n=60, 31.4%). With a median follow-up duration of 3.9 years, the 3-year progression-free survival (PFS) and overall survival (OS) rates were 39.5% and 60.4%, respectively. The role of upfront ASCT was evaluated in patients who were considered transplant-eligible (n=59). ASCT was performed as an upfront consolidative treatment in 32 (54.2%) of these patients. There were no significant differences in PFS and OS between the ASCT and non-ASCT groups for all patients (n=59) and for patients with PTCL-NOS (n=26). However, in patients with AITL, the ASCT group was associated with significantly better PFS than the non-ASCT group, although there was no significant difference in OS.
Conclusion
The current study demonstrated that the survival outcomes with the current treatment options remain poor for patients with PTCL-NOS. Upfront ASCT may provide a survival benefit for patients with AITL, but not PTCL-NOS.

Citations

Citations to this article as recorded by

Epigenetic landscape of angioimmunoblastic T-cell lymphoma: From molecular pathogenesis to precision therapeutics
Ang Li, Hao Hu, Xuefei Liu, Na Xiao, Feizhen Wu, Miaoxia He
Genes & Diseases.2026; : 102064. CrossRef
Risk Factors of Disseminated Tumor Cells in the Bone Marrow of Patients With Angioimmunoblastic T‐Cell Lymphoma and Their Impact on Prognosis
Dongyao Yan, Xueyan Cao, Xiaoqian Wang, Baohong Yue
International Journal of Laboratory Hematology.2026;[Epub] CrossRef
Angioimmunoblastic T-cell lymphoma: a concise overview encompassing the pathogenetic, pathological, clinical, therapeutical characteristics, and recent advances
Yan Feng, Yaxian Ma, Tongjuan Li, Min Liu, Zetong Hong, Qing Yin, Miao Zheng
Clinical and Experimental Medicine.2025;[Epub] CrossRef
Nodal peripheral T‐cell lymphoma in Finland between 2007 and 2019: Incidence, late morbidity and survival
Anu Partanen, Aino Rönkä, Anna Anttalainen, Liisa Ukkola‐Vuoti, Iiro Toppila, Hanne Kuitunen, Tatu Miettinen, Outi Kuittinen
British Journal of Haematology.2025; 207(3): 851. CrossRef
Successful Treatment, with Chemotherapy and Intravenous Administration of Ascorbic Acid, of a Patient with Peripheral T-Cell Lymphoma, Not Otherwise Specified
Chiaki Tokoro, Atsushi Tashiro, Kenji Ina, Yoshiteru Tanaka, Hiroyuki Kobayakawa, Takashi Yoshida, Satoshi Kayukawa
Journal of Cancer Research Updates.2024; 13: 1. CrossRef
Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis
L. Girard, Y. J. Koh, L. P. Koh, Y. L. Chee, H. L. Chan, J. Lee, S. de Mel, L. M. Poon, M. Samuel
Bone Marrow Transplantation.2024; 59(6): 838. CrossRef
Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances
Luís Alberto de Pádua Covas Lage, Hebert Fabricio Culler, Cadiele Oliana Reichert, Sheila Aparecida Coelho da Siqueira, Juliana Pereira
Frontiers in Oncology.2023;[Epub] CrossRef
Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma
Qingyang Zhang, Le Yin, Qinqiao Lai, Yan Zhao, Hongling Peng
Clinical and Experimental Medicine.2023; 23(8): 4219. CrossRef

8,732 View
230 Download
6 Web of Science
8 Crossref

Induction Chemotherapy of Docetaxel and Cisplatin for the Elderly Patients with Squamous Cell Carcinoma of the Head and Neck: Young-Jin Choi, Jooseop Chung, Ho-Jin Shin, Goon-Jae Cho, Soo-Geun Wang, Byung-Joo Lee, Byung-Mann Cho, Dong-Won Kim, Hak-Jin Kim, Won Sik Lee, Young-Don Joo, Chang-Hak Sohn; Cancer Res Treat. 2007;39(1):1-5. Published online March 31, 2007; DOI: https://doi.org/10.4143/crt.2007.39.1.1

Abstract PDF PubReader ePub

Purpose

Although concurrent chemoradiotherapy (CCRT) has been considered as a standard treatment for locally advanced squamous cell carcinoma of the head and neck (SCCHN), this treament is associated with increased toxicities such as mucositis and dermatitis. As a result, the dose intensity can be reduced and interruptions of radiotherapy are more common for CCRT than for sequential treatment, especially for the elderly patients. This prospective study was performed to assess the efficacy and safety profiles of the induction chemotherapy of docetaxel and cisplatin for elderly patients with locally advanced SCCHN.

Materials and Methods

Patients over 65 years of age with locally advanced SCCHN were treated with docetaxel (70 mg/m²) and cisplatin (75 mg/m²) every 21 days. The chemotherapy consisted of two cycles with a third cycle that was administered to the responding patients. Patients who did not respond to initial chemotherapy underwent radiotherapy as a definitive local treatment.

Results

Fifty patients were enrolled in this study and 44 patients were assessable for response and toxicity. The overall response rate was 88%, 16 patients (36%) achieved a complete response and 23 patients (52%) achieved a partial response. After a median follow-up of 24 months (range: 9~38 months) the median disease free period and overall survival period had not yet been reached. The one year and two year survival rates were 89% and 70%, respectively. The most common grade 3/4 adverse event was neutropenia, which occurred in 33 patients (75%) and 4 patients had febrile neutropenia.

Conclusion

Combination chemotherapy of docetaxel and cisplatin is an effective regimen with an acceptable safety profile as the induction treatment for elderly patients suffering with SCCHN.

Citations

Citations to this article as recorded by

Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced head and neck squamous cell carcinoma: A real-world data study
Matheus Yung Perin, Vivian Naomi Horita, Daniel Naves Araújo Teixeira, Joyce Gruenwaldt, Eduardo Baldon Pereira, Carlos Takahiro Chone, Gustavo Jacob Lourenço, Ligia Traldi Macedo, Carmen Silvia Passos Lima
Brazilian Journal of Otorhinolaryngology.2025; 91(3): 101572. CrossRef
THERAPEUTIC OPTIONS FOR ELDERLY PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK CANCERS: PRINCIPLES OF GERIATRIC ONCOLOGY
Camil Ciprian Mirestean, Roxana Irina Iancu , Dragos Petru Teodor Iancu
Romanian Journal of Oral Rehabilitation.2025; 17(2): 677. CrossRef
Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer
Vanita Noronha, Vijay Patil, Pankaj Chaturvedi, Vijayalakshmi Mathrudev, Nandini Menon, Atanu Bhattacharjee, Ajay Singh, Zoya Peelay, Shatabdi Chakraborty, Monica Jadhav, Mitali Alone, Priyanka Bhagyavant, Manali Kolkur, Sujay Srinivas, Sudeep Das, Somnat
European Journal of Cancer.2024; 200: 113560. CrossRef
Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)
Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Jung Hye Kwon, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun
BMC Cancer.2020;[Epub] CrossRef
Treatment of inoperable elderly head and neck cancer patients
Joël Guigay, Hervé Le Caer, Cécile Ortholan, Anne Aupérin, Cécile Michel, Cécile Mertens
Current Opinion in Oncology.2019; 31(3): 152. CrossRef
Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma
Francesca De Felice, Luigia Vetrone, Nadia Bulzonetti, Rossella Caiazzo, Francesco Marampon, Daniela Musio, Vincenzo Tombolini
Medical Oncology.2019;[Epub] CrossRef
Radiotherapy in late elderly (aged 75 or older) patients with paranasal sinus carcinoma: a single institution experience
Hiroshi Doi, Kazuhiro Kitajima, Masao Tanooka, Tomonori Terada, Kazuma Noguchi, Yasuhiro Takada, Masayuki Fujiwara, Reiichi Ishikura, Norihiko Kamikonya, Shozo Hirota
European Archives of Oto-Rhino-Laryngology.2016; 273(12): 4485. CrossRef
Treatment of head and neck cancer in the elderly
Stefan Hartmann, Jennifer R. Grandis
Expert Opinion on Pharmacotherapy.2016; 17(14): 1903. CrossRef
Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines
SINDHU VALIYAVEEDAN GOVINDAN, SAFEENA KULSUM, RAMANAN SOMASUNDARA PANDIAN, DEBASHISH DAS, MUKUND SESHADRI, WESLEY HICKS, MONI ABRAHAM KURIAKOSE, AMRITHA SURESH
Molecular Medicine Reports.2015; 12(2): 3025. CrossRef
The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer
Jae-Sook Ahn, Sang-Hee Cho, Ok-Ki Kim, Joon-Kyoo Lee, Deok-Hwan Yang, Yeo-Kyeoung Kim, Je-Jung Lee, Sang-Chul Lim, Hyeoung-Joon Kim, Woong-Ki Chung, Ik-Joo Chung
Cancer Research and Treatment.2007; 39(3): 93. CrossRef

10,861 View
69 Download
10 Crossref

A Multi-Center, Phase II Clinical Trial of Padexol™ (Paclitaxel) and Cisplatin for Patients Suffering with Advanced Gastric Cancer: Min Kyoung Kim, Kyung Hee Lee, Myung Soo Hyun, Young Rok Do, Hong Suk Song, Won Sik Lee, Keon Uk Park, Jin Ho Baek, Jong Gwang Kim; Cancer Res Treat. 2005;37(6):349-353. Published online December 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.6.349

Abstract PDF PubReader ePub

Purpose

We conducted a multi-center, phase II trial to evaluate the efficacy and safety of using Padexol (a paclitaxel formulation) combined with cisplatin for the patients suffering with advanced gastric adenocarcinoma.

Materials and Methods

39 patients (median age: 60 years; males: 90%) who were diagnosed with advanced gastric cancer were enrolled from 5 hospitals. Padexol 175 mg/m² was administered as a 3-hr infusion, and this was followed by cisplatin 75 mg/m² as an intravenous infusion on day 1, once every 3 weeks.

Results

Out of these 39 patients, 34 patients were assessable for treatment efficacy and 39 patients were assessable for the toxicity. Objective responses occurred in 13 patients (33%); 1 patient (3%) had a complete response and 12 patients (31%) had partial responses. 6 patients (15%) achieved a stable disease state. The median duration of response was 7.1 months, and the median time to progression and the overall survival were 4.8 months and 6.7 months, respectively. The major treatment-related adverse events were hematologic toxicity, including WHO grade 3 or 4 neutropenia in 13 patients (33%). However, febrile neutropenia occurred in only 1 patient and the non-hematologic toxicity was usually mild.

Conclusion

The combination of Padexol and cisplatin was found to be active and it seems to be a relatively well-tolerated regimen for the treatment of advanced gastric cancer.

Citations

Citations to this article as recorded by

Effect of the Weekly Administration of Liposome–Paclitaxel Combined with S-1 on Advanced Gastric Cancer
Lei Chen, Qiang Chen, Zhixiang Zhuang, Yusong Zhang, Jialong Tao, Liqin Shen, Xudong Shen, Zhigang Chen, Ji Wang, Minggao Zhu, Hui Wang
Japanese Journal of Clinical Oncology.2014; 44(3): 208. CrossRef
Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer
Jin Young Kim, Young Rok Do, Keon Uk Park, Jong Gwang Kim, Yee Soo Chae, Min Kyoung Kim, Kyung Hee Lee, Hun Mo Ryoo, Sung Hwa Bae, Jin Ho Baek, Hong Suk Song
Cancer Chemotherapy and Pharmacology.2011; 67(3): 527. CrossRef
Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer
Yuji Ueda, Hisakazu Yamagishi, Daisuke Ichikawa, Kazuma Okamoto, Eigo Otsuji, Jun Morii, Kinya Koizumi, Naoki Kakihara, Masataka Shimotsuma, Tetsuro Yamashita, Fumihiro Taniguchi, Hideki Aragane, Hiroshi Nishi, Yoshiki Itokawa, Satoshi Morita, Junichi Sak
Gastric Cancer.2010; 13(3): 149. CrossRef
TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin
Jong Gwang Kim, Sang Kyun Sohn, Yee Soo Chae, Hong Suk Song, Ki-Young Kwon, Young Rok Do, Min Kyoung Kim, Kyung Hee Lee, Myung Soo Hyun, Won Sik Lee, Chang-Hak Sohn, Joo Seop Jung, Gab Chul Kim, Ho Young Chung, Wansik Yu
Cancer Chemotherapy and Pharmacology.2009; 64(2): 355. CrossRef
Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer
Q. Sun, C. Liu, H. Zhong, B. Zhong, H. Xu, W. Shen, D. Wang
Japanese Journal of Clinical Oncology.2009; 39(4): 237. CrossRef
A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer
Bong-Gun Seo, Sung Yong Oh, Dong Mee Lee, Hyun Seung Yoo, Suee Lee, Seong-Geun Kim, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim
Cancer Research and Treatment.2007; 39(1): 6. CrossRef
Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer
Jong Gwang Kim, Sang Kyun Sohn, Hong Suk Song, Ki-Young Kwon, Young Rok Do, Kyung Hee Lee, Myung Soo Hyun, Hun Mo Ryoo, Sung Hwa Bae, Keon Uk Park, Jin Ho Baek, Won Sik Lee, Joo Seop Chung, Goon Jae Cho, Chang-Hak Sohn, Jung Soon Jang, Ho Young Chung, Wan
Cancer Chemotherapy and Pharmacology.2007; 60(6): 863. CrossRef
The Efficacy and Safety of Padexol® (Paclitaxel) and Cisplatin for Treating Advanced Non-small Cell Lung Cancer
Hoon-Kyo Kim, Jun Suk Kim, Hun Mo Ryoo, Dong Gun Shin, Byoung Young Shim, Kyong Hwa Park, Sung Hwa Bae, Chi Hong Kim
Cancer Research and Treatment.2006; 38(2): 66. CrossRef

11,754 View
72 Download
8 Crossref

First
Prev
Page of 1
Next
Last

Search